Analytical Data
-
Gene name
MAP1LC3B
- Application
-
Alternative Names
MAP1A/1BLC3; ATG8F; Autophagy-related ubiquitin-like modifier LC3 B; MAP1 light chain 3-like protein 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9GZQ8
-
Expression Region
Met1~Gly120
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAP1LC3B, a member of the microtubule-associated protein 1 light chain 3 family, plays a crucial role in autophagy, a cellular process essential for maintaining cellular homeostasis and responding to stress. Research has shown that MAP1LC3B is involved in the formation of autophagosomes, the structures that engulf cellular debris and pathogens for degradation. Its expression and activation are often upregulated in various conditions, including cancer, neurodegenerative diseases, and infections, highlighting its potential as a biomarker and therapeutic target. The study of MAP1LC3B not only provides insights into the molecular mechanisms governing autophagy but also reveals its implications in disease progression and pathology. Understanding the functional dynamics of MAP1LC3B and its interactions with other cellular components is critical for elucidating how dysregulation of autophagy contributes to various diseases and for developing strategies to modulate this process for therapeutic benefit. Efforts to create recombinant MAP1LC3B proteins have facilitated mechanistic studies, enabling researchers to investigate autophagy regulation and MAP1LC3B’s potential in treatment strategies against a broad spectrum of diseases.
